COCP Stock Price, Cocrystal Pharma Inc Quote, Chart

Market Summary

USD1.99+0.02

Delayed

1.02%

COCP Stock Price

View Fullscreen

COCP RSI Chart

COCP Valuation

Market Cap

20.2M

Price/Earnings (Trailing)

-1.21

Price/Sales (Trailing)

8.74

EV/EBITDA

0.21

Price/Free Cashflow

-1.25

COCP Price/Sales (Trailing)

COCP Profitability

EBT Margin

-479.05%

Return on Equity

-74.17%

Return on Assets

-63.1%

Free Cashflow Yield

-79.72%

COCP Fundamentals

COCP Revenue

Revenue (TTM)

2.0M

COCP Earnings

Earnings (TTM)

-16.8M

Earnings Growth (Yr)

23.76%

Earnings Growth (Qtr)

11.38%

Breaking Down COCP Revenue

Last 7 days

15.0%

Last 30 days

39.2%

Last 90 days

26.8%

Trailing 12 Months

-13.5%

How does COCP drawdown profile look like?

COCP Financial Health

Current Ratio

10.3

Debt/Equity

0.09

Debt/Cashflow

-7.88

COCP Investor Care

Diluted EPS (TTM)

-1.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	1.9M	1.9M	1.9M	2.0M
2019	3.8M	4.7M	5.6M	6.6M
2018	0	0	2.0M	2.9M
2016	100.0K	112.0K	1.0M	0
2015	6.2M	4.1M	2.1M	78.0K
2014	0	0	0	8.2M
2013	15.9M	12.9M	10.3M	0
2012	13.5M	15.8M	16.6M	17.3M
2011	14.6M	14.0M	13.4M	12.8M
2010	0	0	0	15.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cocrystal Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2023	frost phillip md et al	bought	2,000,000	1.97	1,015,230	-
Aug 20, 2021	pfenniger richard c jr	bought	41,120	1.028	40,000	-
May 04, 2021	schinazi raymond f	sold	-1,696,250	2.95	-575,000	-
Oct 25, 2019	schinazi raymond f	bought	9,091	1.15	7,906	-
Oct 24, 2019	schinazi raymond f	bought	5,858	1.15	5,094	-
Oct 23, 2019	schinazi raymond f	bought	4,086	1.0386	3,935	-

Which funds bought or sold COCP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-6,600	34,953	-%
May 15, 2024	MORGAN STANLEY	reduced	-0.01	-19,108	82,979	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.04	-2,897	12,565	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	27.58	376	10,439	-%
May 15, 2024	Royal Bank of Canada	added	466	-	-	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	-3,933	17,090	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-16,318	86,436	-%
May 13, 2024	FMR LLC	sold off	-100	-7.00	-	-%
May 13, 2024	UBS Group AG	added	12,030	28,073	28,361	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	0.72	-39,000	176,000	-%

Are Funds Buying or Selling COCP?

Are funds buying COCP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own COCP

No. of Funds

Unveiling Cocrystal Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	sabby management, llc	12.%	0	SC 13G/A
Apr 14, 2023	frost phillip md et al	13.1%	1,332,608	SC 13D/A
Apr 12, 2023	hassan fred	10.0%	1,015,229	SC 13G
Jan 10, 2023	sabby management, llc	5.17%	420,710	SC 13G/A
Jan 04, 2022	sabby management, llc	5.89%	5,738,120	SC 13G/A
Jun 10, 2021	frost phillip md et al	3.8%	3,726,306	SC 13D/A
May 25, 2021	fivet investment management ltd	0.00%	0	SC 13D
May 17, 2021	ayrton capital llc	6.69%	6,520,000	SC 13G
May 12, 2021	sabby management, llc	9.99%	9,740,000	SC 13G
Feb 16, 2021	cvi investments, inc.	-	0	SC 13G/A

Recent SEC filings of Cocrystal Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 07, 2024	DEF 14A	DEF 14A
May 01, 2024	8-K	Current Report
Apr 26, 2024	PRE 14A	PRE 14A
Apr 17, 2024	10-K/A	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 19, 2024	8-K	Current Report
Mar 01, 2024	8-K	Current Report

Peers (Alternatives to Cocrystal Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cocrystal Pharma Inc News

Latest updates

Cocrystal Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2013Q3	2013Q2	2013Q1
Revenue	4.3%	510	489	554	461	402	492	592	5,078	3,818	2,559	1,299	39.00	49.00	-	24.00	27.00	714	1,400	2,087	1,956	2,029
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,110	552	592
Operating Expenses	-38.2%	1,976	3,198	4,004	2,422	48,327	2,300	2,142	2,201	56,305	2,419	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	14.0%	1,278	1,121	2,028	1,139	1,266	1,223	1,051	1,323	1,196	952	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-66.4%	698	2,077	1,976	1,283	958	1,077	1,091	878	1,204	1,467	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0%	2.00	2.00	2.00	2.00	9.00	5.00	5.00	-6.00	-3.00	500*	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-12,124	-483	-	-	-	15,300	-	-52.00	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-47,845	-1,780	-1,515	2,971	-56,409	-2,351	-1,881	-3,227	-	-	-	-	-	-	-6,058	-	-
Net Income	44.1%	-1,493	-2,670	-3,495	-1,990	-47,845	-1,780	-1,515	2,971	-44,286	-1,868	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-15.1%	27.00	31.00	33.00	36.00	38.00	41.00	46.00	52.00	75.00	79.00	83.00	87.00	54.00	54.00	53.00	40.00	43.00	29.00	73.00	75.00	76.00
Current Assets	-15.8%	24.00	29.00	32.00	36.00	37.00	40.00	45.00	52.00	55.00	59.00	62.00	67.00	34.00	34.00	33.00	20.00	23.00	8.00	7.00	9.00	10.00
Cash Equivalents	-17.1%	22.00	26.00	30.00	32.00	34.00	37.00	42.00	51.00	55.00	59.00	62.00	67.00	33.00	33.00	32.00	19.00	22.00	7.00	6.00	7.00	9.00
Net PPE	-10.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	-	-	-	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	65.00	65.00	65.00
Liabilities	-18.7%	4.00	5.00	2.00	2.00	3.00	1.00	2.00	3.00	2.00	2.00	2.00	3.00	2.00	2.00	3.00	3.00	2.00	3.00	3.00	2.00	2.00
Current Liabilities	-27.1%	2.00	3.00	2.00	2.00	3.00	1.00	2.00	3.00	2.00	2.00	1.00	2.00	1.00	1.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00
Shareholder's Equity	-14.4%	23.00	26.00	31.00	0.00	35.00	40.00	50.00	49.00	74.00	78.00	81.00	85.00	52.00	53.00	50.00	37.00	40.00	26.00	71.00	72.00	74.00
Retained Earnings	-1.3%	-319	-315	-311	-307	-303	-297	-293	-287	-263	-259	-255	-251	-247	-244	-243	-240	-237	-235	-187	-185	-184
Additional Paid-In Capital	0.0%	342	342	342	342	338	337	337	337	337	337	336	336	300	297	294	278	278	261	258	258	258
Shares Outstanding	0.0%	10.00	10.00	10.00	10.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	6.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	19.00	-	-	-	38.00	-	-	-	116	-	-	-	64.00	-	-	-	38,555	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-35.4%	-4,503	-3,326	-2,681	-5,548	-3,111	-4,893	-8,908	-3,724	-3,910	-2,922	-5,403	-2,624	-1,770	-2,381	-3,061	-2,200	-2,188	-1,230	-1,323	-1,028	2,018
Share Based Compensation	-0.6%	157	158	173	179	291	159	216	241	239	222	205	78.00	219	199	237	119	107	138	108	33.00	33.00
Cashflow From Investing	86.4%	-8.00	-59.00	-	-14.00	-45.00	-12.00	-	-	-	-8.00	-4.00	-15.00	-25.00	-1.00	-19.00	-127	-93.00	-1.00	-115	-4.00	-25.00
Cashflow From Financing	-	-	-	-	4,000	-7.00	-7.00	-7.00	-7.00	-6.00	-9.00	-11.00	36,423	2,063	3,611	15,546	-44.00	16,549	2,655	-42.00	-65.00	3,876

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

COCP Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 2,950	$ 3,907
General and administrative	1,208	1,204
Total operating expenses	4,158	5,111
Loss from operations	(4,158)	(5,111)
Other income (expense):
Interest income (expense), net	220
Foreign exchange loss	(18)	(78)
Total other income (expense), net	202	(78)
Net loss	$ (3,956)	$ (5,189)
Net loss per common share, basic	$ (0.39)	$ (0.64)
Net loss per common share, diluted	$ (0.39)	$ (0.64)
Weighted average number of common shares, basic	10,174	8,143
Weighted average number of common shares, diluted	10,174	8,143

COCP Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 21,842,000	$ 26,353,000
Restricted cash	75,000	75,000
Tax credit receivable	1,003,000	890,000
Prepaid expenses and other current assets	1,572,000	1,773,000
Total current assets	24,492,000	29,091,000
Property and equipment, net	244,000	271,000
Deposits	46,000	46,000
Operating lease right-of-use assets, net (including $26 and $42 to related party)	1,764,000	1,851,000
Total assets	26,546,000	31,259,000
Current liabilities:
Accounts payable and accrued expenses	2,139,000	3,022,000
Current maturities of operating lease liabilities (including $26 and $42 to related party)	240,000	240,000
Total current liabilities	2,379,000	3,262,000
Long-term liabilities:
Operating lease liabilities (including $0 and $0 to related party)	1,582,000	1,613,000
Total long-term liabilities	1,582,000	1,613,000
Total liabilities	3,961,000	4,875,000
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 a par value: 150,000 shares authorized as of March 31, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of March 31, 2024 and December 31, 2023	10,000	10,000
Additional paid-in capital	342,445,000	342,288,000
Accumulated deficit	(319,870,000)	(315,914,000)
Total stockholders’ equity	22,585,000	26,384,000
Total liabilities and stockholders’ equity	$ 26,546,000	$ 31,259,000

About Cocrystal Pharma Inc

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

CEO	Dr. Sam Lee Ph.D.
WEBSITE	cocrystalpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	12

Cocrystal Pharma Inc Frequently Asked Questions

What is the ticker symbol for Cocrystal Pharma Inc? What does COCP stand for in stocks?

COCP is the stock ticker symbol of Cocrystal Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cocrystal Pharma Inc (COCP)?

As of Fri May 17 2024, market cap of Cocrystal Pharma Inc is 20.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COCP stock?

You can check COCP's fair value in chart for subscribers.

What is the fair value of COCP stock?

You can check COCP's fair value in chart for subscribers. The fair value of Cocrystal Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cocrystal Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for COCP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cocrystal Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether COCP is over valued or under valued. Whether Cocrystal Pharma Inc is cheap or expensive depends on the assumptions which impact Cocrystal Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COCP.

What is Cocrystal Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, COCP's PE ratio (Price to Earnings) is -1.21 and Price to Sales (PS) ratio is 8.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COCP PE ratio will change depending on the future growth rate expectations of investors.